{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:10:35Z","timestamp":1790413835527,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1984,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:p><jats:bold>Study Objective<\/jats:bold>. To assess the effectiveness of using low\u2010dose recombinant activated factor VII (rFVIIa) to reverse the effects of warfarin in critically ill patients with major bleeding events.<\/jats:p><jats:p><jats:bold>Design<\/jats:bold>. Prospective observational study.<\/jats:p><jats:p><jats:bold>Setting<\/jats:bold>. Intensive care unit of a 500\u2010bed university\u2010affiliated hospital.<\/jats:p><jats:p><jats:bold>Patients<\/jats:bold>. Sixteen nonhemophiliac patients who had been receiving warfarin and had an acute major bleeding event.<\/jats:p><jats:p><jats:bold>Intervention<\/jats:bold>. Patients received rFVIIa 1.2 mg for reversal of anticoagulation.<\/jats:p><jats:p><jats:bold>Measurements and Main Results<\/jats:bold>. Patients were identified from clinical pharmacology consult service electronic tracking records, and their data were cross\u2010checked with the pharmacy information system. Information collected for each patient included extent of bleeding and magnitude of elevation in international normalized ratio (INR). A mean \u00b1 SD dose of rFVIIa 16.3 \u00b1 4.1 \u03bcg\/kg (range 11\u201325 \u03bcg\/kg) reduced the mean INR from 2.8 \u00b1 1.6 (range 1.44\u20136.34) to 1.07 \u00b1 0.27 (range 0.86\u20131.92, p&lt;0.001). A rapid onset of response for achieving a desirable hemostatic effect was observed in 14 of the 16 patients.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold>. Low\u2010dose rFVIIa appears to be an effective, rapid reversal modality for major bleeding events in the presence of warfarin and an elevated INR. The agent's response is quicker than that expected with fresh frozen plasma combined with vitamin K. In emergency situations, rFVIIa 1.2 mg can be used to reverse the anticoagulant effect of warfarin and other vitamin K antagonists without inducing a hypercoagulable state; the product, however, is expensive.<\/jats:p>","DOI":"10.1592\/phco.26.8.1091","type":"journal-article","created":{"date-parts":[[2006,7,25]],"date-time":"2006-07-25T07:57:35Z","timestamp":1153814255000},"page":"1091-1098","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Reversal of Elevated International Normalized Ratios and Bleeding with Low\u2010Dose Recombinant Activated Factor VII in Patients Receiving Warfarin"],"prefix":"10.1002","volume":"26","author":[{"given":"William E.","family":"Dager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff H.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron C.","family":"Regalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Steven","family":"Tharratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Albertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.204S"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199911000-00020"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.008904"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199811000-00003"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615148"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00711.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1055\/s-0038-1655992","article-title":"Emergency oral anticoagulation reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy","volume":"77","author":"Markis M.","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00220.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/hs1101.098523"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.19.2136"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.20.2469"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03070.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-0502(03)00047-8"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2003.12.003"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-8180(03)00034-5"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH03-10-0638"},{"key":"e_1_2_1_18_2","first-page":"CS98","article-title":"Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin\u2010related coagulation in patients with acute subdural hematoma","volume":"8","author":"Veshchev I.","year":"2002","journal-title":"Med Sci Monit"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"a4015","DOI":"10.1182\/blood.V104.11.4015.4015","article-title":"Clinical outcomes of recombinant activated factor VII (rVIIa) use in a tertiary care hospital: 70 treatment courses in 63 patients [abstr]","volume":"104","author":"Deloughery T.G.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2003.98.4.0737"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TA.0000140646.66852.AB"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2003.11.011"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-11-200212030-00009"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00759.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199912000-00010"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200307000-00007"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042991"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00922.x"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05155-7"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-8464"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000195047.21562.23"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00943.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000149628.80251.b8"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.3.293"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.26.8.1091","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.26.8.1091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:32:11Z","timestamp":1761057131000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.26.8.1091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1592\/phco.26.8.1091"],"URL":"https:\/\/doi.org\/10.1592\/phco.26.8.1091","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}